Patheon, the Canadian drug builder with domicile in Research Triangle Park, reported an uptick in first-quarter sales but a decrease in distinction as well as an handling loss.
The association employs about 50 people in RTP and about 4,200 worldwide. Patheon produces pharmaceuticals and alternative services for vital drug makers.
Sales were $154.8 million in the initial quarter, up 5.2 percent from the same three-month duration last year. But Patheon posted an handling loss of $6.6 million, compared with handling income of $3.9 million a year ago. Gross distinction fell to $24.6 million from $30.7 million.
Patheon attributed the declines to losses compared with acquisitions and consolidations, as well as disappearing direct from customers. The association has been slicing jobs via the retrogression to sojourn competitive.
Staff bard John Murawski
No comments:
Post a Comment